Phaseline

Companies › Bioventus

Bioventus: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PTP-001
Allogeneic human placental tissue particulate
–Phase 2Osteoarthritis, Knee–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05100225PTP-001Phase 2Osteoarthritis, KneeImmunologyOct 2022

From the company's SEC filings

Cash of $31m on 2026-09-26; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Clinuvel Aravax VivaTech International AltruBio Qu Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.